Managing Staff Training And GMP Compliance - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Managing Staff Training And GMP Compliance
A case study is presented that describes how a software control system can ease the complex task of managing training needs across an international company, and improve GMP compliance by ensuring that employees are aptly qualified to perform their assigned tasks.


Pharmaceutical Technology Europe
Volume 22, Issue 12

The reporting system

A reporting system provides oversight of all training required and performed. One of the reports most frequently needed by management is the evaluation of training of one specific document; for example, to verify if all persons who need to be trained in a certain SOP have already been trained in the current version of the SOP. This functionality may seem basic, but it is extremely helpful in providing an overview about the training status of specific jobs, mapped with job profiles. Roche established such a matrix with an integrated Pharmschul report, which is a graphical list where compliance and (hopefully no) gaps are visible at a glance. The actual training status of employees is automatically reported periodically to management, providing line managers with transparent information of their responsibility in ensuring personnel are trained accordingly. We have found that this information has led to a high status of compliance.

A KPI report for the higher management is also regularly used. Our higher level management forces the monitoring of KPIs, with all employees having a dedicated amount of training to be performed per defined period. The ratio between the total number of trainings, and the planned/required training has to be reported regularly, and helps to justify adequate resources for the technical and GxP training of staff.

Conclusion

Managing GMP training is a complex task, particularly in large companies where Excel spreadsheets and certificate archives are not feasible. Because of this, Roche implemented a professional GMP training system that helps to identify and evaluate training needs, and assign these to each individual in the company. Only with a complete system in place can large companies ensure that every employee receives the necessary information and training.

References

1. ECA Foundation, FDA Warning Letter Report (2010). http://www.gmp-compliance.org/

2. U. Schaffer and O. Schmidt, Die Pharmazeutische Industrie, 68(10), 1149–1152 (2006).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
21%
To all process for new products only
13%
To select process for new products only
26%
To select processes for both new and legacy products
21%
Do not use QbD
21%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology Europe,
Click here